Publications by authors named "Annie Veyre"
Article Synopsis
- SIMS is a valuable tool for studying how radiopharmaceuticals like I-BZA distribute in melanoma cells and related tissues.
- I-BZA was found to accumulate in the cytoplasm of both melanoma cells and certain immune cells, with retention explained by melanin-containing organelles.
- The study showed that the labeled and unlabeled forms of I-BZA distributed similarly, suggesting a stable molecular structure, and indicated a retention half-life of about 38 hours in melanosomes.
N-(2-diethylaminoethyl)-2-iodobenzamide (BZA(2)) has been singled out as the most efficacious melanoma scintigraphy imaging agent. Our work was designed to assess the mechanisms of the specific affinity of the radioiodinated iodobenzamide for melanoma tissue. We studied the cellular uptake and retention of [(125)I]-BZA(2) on various cell lines.
View Article and Find Full Text PDF123I-N-(2-diethylaminoethyl)-2-iodobenzamide: a potential imaging agent for cutaneous melanoma staging.
Eur J Nucl Med Mol Imaging
November 2002
Melanoma is a neoplasia of dramatically increasing incidence that has a propensity to spread rapidly. Early detection is fundamental and patient management requires reliable, sensitive and reproducible staging methods, such as a single examination by planar scintigraphy or single-photon emission tomography (SPET) using a radiopharmaceutical with selectivity for melanoma tissue. Among iodobenzamides reported to possess an affinity for melanoma, a new compound, N-(2-diethylaminoethyl)-2-iodobenzamide (BZA(2)), was selected for a clinical trial in view of its pharmacokinetic experimental profile in melanoma-bearing mice.
View Article and Find Full Text PDF